- Home
- GGT vs ZNTL Comparison
GGT vs ZNTL Comparison
Compare GGT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGT | ZNTL |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 156.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GGT | ZNTL |
|---|---|---|
| Price | $3.99 | $2.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 298.6K | ★ 557.3K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | N/A | ★ 47.87 |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $67,425,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.75 | $1.01 |
| 52 Week High | $4.76 | $3.95 |
Technical Indicators
Market Signals| Indicator | GGT | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 53.40 |
| Support Level | $3.93 | $1.29 |
| Resistance Level | $4.29 | $2.69 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 19.74 | 32.46 |
Price Performance
Historical ComparisonAbout GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.